A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARγ to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction
- 1 August 2013
- journal article
- Published by Elsevier in International Journal of Cardiology
- Vol. 167 (4) , 1298-1304
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- EPCs and pathological angiogenesis: When good cells go badMicrovascular Research, 2010
- Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formationMicrovascular Research, 2010
- Systems biology of pro‐angiogenic therapies targeting the VEGF systemWIREs Mechanisms of Disease, 2010
- Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approachesJournal of Molecular and Cellular Cardiology, 2009
- Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseasesNature Reviews Drug Discovery, 2009
- Combination of stromal-derived factor-1α and vascular endothelial growth factor gene-modified endothelial progenitor cells is more effective for ischemic neovascularizationJournal of Vascular Surgery, 2009
- Endothelial progenitor cells in neovascularization of infarcted myocardiumJournal of Molecular and Cellular Cardiology, 2008
- Orally Bioavailable Potent Soluble Epoxide Hydrolase InhibitorsJournal of Medicinal Chemistry, 2007
- Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitorsProceedings of the National Academy of Sciences, 2006
- Therapeutic stem and progenitor cell transplantation for organ vascularization and regenerationNature Medicine, 2003